Skip to main content
Caplight Logo









Spryte Medical

Spryte Medical

Private
Bedford, MassachusettsHealthcare & Life Scienceshttps://sprytemedical.com/

Last Round

Strategic

Mar 25, 2026

Est. Valuation

$80.03M

Total Funding Raised

$93.45M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Spryte Medical is a medical device company developing an AI-enabled neuro Optical Coherence Tomography (nOCT) platform for intravascular imaging of the brain.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging, Medical AI

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales, Usage-Based SaaS

AI Layer

Application

Keywords

intravascular imagingnOCTneurovascular imagingoptical coherence tomographyOCTneurointerventional deviceaneurysm treatmentstroke treatmentFDA breakthrough deviceAI medical imagingendovascular treatmentmedical device consumablesinvestigational medical device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Spryte Medical Comparables

Compare Spryte Medical with similar companies based on industry and business-model similarity.

Spryte Medical comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Gentuity
86%
Vena Medical
78%
Philips
70%

Spryte Medical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMar 25, 2026
M&ADec 19, 2025
SeedJun 5, 2024

Key People

Founding team and executive leadership

David W. Kolstad

Chief Executive Officer

Executive Team

Renny Clark

Executive Vice President and Chief Financial Officer

Executive Team

Spryte Medical Investors

Notable investors and investment history

Spryte Medical investors
InvestorRounds
Development Bank of JapanStrategic
Adams Street PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 25, 2026

    Led by Development Bank of Japan

  • Dec 19, 2025

    $49M round led by Nipro Corp.

Spryte Medical Filings

Explore SEC and related filing metadata, where available.

Spryte Medical filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Spryte Medical's valuation, stock price, and market status.

Is Spryte Medical a public or private company?

Spryte Medical is a private company.

What is the current stock price of Spryte Medical?

Spryte Medical is a private company with no public stock price. No recent secondary market data is available.

How much is Spryte Medical worth (valuation)?

Spryte Medical's valuation is estimated at $80.0M based on funding round data.

Can I buy Spryte Medical stock?

Spryte Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Spryte Medical's last funding round?

Spryte Medical's most recent funding round was Strategic on December 19, 2025.

Who are the main investors in Spryte Medical?

Key investors in Spryte Medical include Development Bank of Japan.

Will Spryte Medical IPO soon?

No public IPO plans have been announced for Spryte Medical.

How can I track Spryte Medical secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Spryte Medical's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBedford, Massachusetts
Year Founded2023
Last FundingMar 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?